Publicado

2017-11-01

In vitro antifungal susceptibility of clinical isolates of Fusarium from Colombia

Susceptibilidad antifúngica in vitro de aislamientos clínicos de Fusarium de Colombia

Palabras clave:

Fusarium, amphotericin B, voriconazole (en)
Fusarium, anfotericina B, voriconazol (es)

Descargas

Autores/as

  • Adelaida Gaviria-Rivera Universidad Nacional de Colombia - Sede Medellín
  • Alejandra Giraldo-López Universidad Nacional de Colombia - Sede Medellín
  • Luz E. Cano Restrepo Universidad de Antioquia

Objective The aim of the present study was to evaluate the antifungal susceptibilities of isolates of Fusarium to amphotericin B, itraconazole and voriconazole.
Methods The susceptibility of 44 isolates of Fusarium was tested by the E-test methodology.
Results All the isolates were resistant to itraconazole, and 89 % and 54,5 % were resistant to amphotericin B and voriconazole, respectively.
Discussion The results confirm the high level of resistance reported, regardless of the species or the strain of Fusarium involved. The high MICs level observed are worrying and suggest that new drugs are needed.

Objetivo Evaluar la susceptibilidad antifúngica in vitro de aislamientos de Fusarium a los antimicóticos amfotericina B, itraconazol y voriconazol.
Métodos La susceptibilidad de 44 aislamientos clínicos de Fusarium fue evaluada por el método de difusión en disco, E-test.
Resultados Todos los aislamientos fueron resistentes al itraconazol, y 89 % y 54,5 % fueron resistentes a la amfotericina B y al voriconazol, respectivamente.
Discusión Los resultados confirman el alto nivel de resistencia reportado, independiente de la especie o la cepa de Fusarium involucrada. Los valores tan altos de MICs son preocupantes y sugieren la necesidad de evaluar nuevos medicamentos.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Tortorano A, Prigitano A, Dho G, Esposto M, Gianni C, Grancini, Ossi C, Viviani M. Species Distribution and In Vitro Antifungal Susceptibility Patterns of 75 Clinical Isolates of Fusarium spp. from Northern Italy. Antimicrob Agents Chemother. 2008; 52 (7): 2683-2685.

García-Ruiz JC, Olazábal I, Adán-Pedroso RM, López-Soria L, Velasco-Benito V, Sánchez-Aparicio JA, Navajas A, Montejo M, Moragues MD. Disseminated fusariosis and hematologic malignancies, a still devastating association. Report of three new cases. Rev Iberoam Micol. 2015; 32(3): 190-6.

Oechsler R, Yamanaka T, Bispo P, Sartoril J, Zorat-Yu M, Melo A, Miller D, Hofling-Lima A. Fusarium keratitis in Brazil: genotyping, in vitro susceptibilities, and clinical outcomes. Clin Ophthalmol. 2013; (7): 1693-1701.

Azor M, Gené J, Cano J, Manikandan P, Venkatapathy N, Guarro J. Species of Clinical Interest: Correlation between Morphological and Molecular Identication and Antifungal Susceptibility. J Clin Microbiol. 2009; 47 (5): 1463-1468.

Al-Hatmi AM, Bonifaz A, de Hoog GS, Vazquez-Maya L, Garcia-Carmona K, Meis JF, van Diepeningen AD. Keratitis by Fusarium temperatum, a novel opportunist. BMC Infect Dis. 2014; 14: 588.

Castro-López N, Casas C, Sopo L, Rojas A, Del-Portillo P, Cepero MC, Restrepo S. Fusarium species detected in onychomycosis in Colombia. Mycoses. 2009; 52 (4): 350-6.

Van-Diepeningen AD, Brankovics B, Iltes J, Van der Lee TA, Waalwijk C. Diagnosis of Fusarium Infections: Approaches to Identification by the Clinical Mycology Laboratory. Curr fungal infect Rep. 2015; (9): 135-143.

Azor M, Gene J, Cano J, Guarro J. Universal In Vitro Antifungal Resistance of Genetic Clades of the Fusarium solani Species Complex. Antimicrob agents and chemother. 2007; 51 (4): 1500-1503.

Mukherjee PK, Chandra J, Yu C, Sun Y, Pearlman E, Ghannoum MA. Characterization of Fusarium Keratitis Outbreak Isolates: Contribution of Biofilm to Antimicrobial Resistance and Pathogenesis. Invest Ophthalmol Vis Sci. 2012; 53 (8): 4450-4457.

Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, de Hoog GS, Meis JF. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother. 2015; 70 (4): 1068-71.

Araujo R, Oliveira M, Amorim A, Sampaio-Maia B. Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. Eur J Clin Microbiol Infect Dis. 2015; 34 (7): 1289-301.

Kredics L, Narendran V, Shobana CS, Vágvõlgyi C, Manikandan P. Filamentous fungal infections of the cornea: a global overview of epidemiology and drug sensitivity. Mycoses. 2015; 58 (4): 243-60.

Drogari-Apiranthitou M, Foteini-Despina M, Skiada A, Kanioura L, Grammatikou M, Vrioni G, Mitroussia-Ziouva A, Tsakris A, Petrikkos G. In vitro antifungal susceptibility of filamentou fungi causing rare infections: synergy testing of amphoteri-cin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother. 2012; 67: 1937-1940.

de Souza M, Matsuzawa T, Lyra L, Busso-Lopes AF, Gonoi T, Schreiber AZ, Kamei K, Moretti ML,Trabasso P. Fusarium napiforme systemic infection: case report with molecular characterization and antifungal susceptibility tests. Springerplus. 2014; 3: 492.

Acevedo-Granados Y, Cano L, Gaviria-Rivera A. Identificación de aislamientos clínicos de Fusarium spp., mediante técnicas moleculares en Colombia. Bistua: Revista de la Facultad de Ciencias Básicas. 2014; 12(1): 143-159.

Clinical and Laboratory Standards Institute (formerly NCCLS). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi-approved standard, 2nd ed. CLSI document M38-A2. CLSI, Wayne, PA, USA; 2008.

Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, Ellis D, Pfaller MA, Messer S, Rinaldi M, Fothergill A, Gibbs DL, Wang A. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol. 2007; 45(6): 1811-20.

Espinel-Ingroff A, Canton E, Fothergill A, Ghannoum M, Johnson E, Jones RN, Ostrosky-Zeichner L, Schell W, Gibbs DL, Wang A, Turnidge J. Quality control guidelines for amphotericin B, Itraconazole, posaconazole, and voriconazole disk diffusion susceptibility tests with non-supplemented Mueller-Hinton Agar (CLSI M51-A document) for nondermatophyte Filamentous Fungi. J Clin Microbiol. 2011; 49 (7): 2568-71

Duarte-Vogel S, Villamil-Jiménez LC. Micotoxinas en la Salud Pública. Rev. Salud Pública (Bogotá). 2006; 8 (Sup 1): 129-135.

Venturini TP, Rossato L, Spader TB, Tronco-Alves GR, Azevedo MI, Weiler CB, Santurio JM, Alves SH. In vitro synergis-ms obtained by amphotericin B and voriconazole associated with non-antifungal agentes against Fusarium spp. Diagn Microbiol Infect Dis. 2011; 71: 126-130.

Fothergill AW. Antifungal Susceptibility Testing: Clinical Laboratory and Standards Institute (CLSI) Methods. In: Interactions of Yeasts, Moulds, and Antifungal Agents: How to Detect Resistance. Hall GS (ed.). Springer, New York 2012. p. 170.

Bueno JG, Martinez C, Zapata B, Sanclemente G, Gallego M, Mesa AC. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clin Exp Dermatol. 2010; 35(6): 658-63.

Stempel JM, Hammond SP, Sutton DA, Weiser LM, Marty FM. Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience. Open Forum Infect Dis. 2015; 4; 2 (3): ofv099. Doi: 10.1093/ofid/ofv099.

Licencia

Derechos de autor 2017 Revista de Salud Pública

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

Esta revista provee acceso libre inmediato a su contenido bajo el principio de que hacer disponible gratuitamente investigación al publico apoya a un mayor intercambio de conocimiento global.

Todos los contenidos de esta revista, excepto dónde está identificado, están publicados bajo una Licencia Creative Commons Atribución 4.0.